Compare IDEXX Laboratories, Inc. (IDXX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs TORM plc — how do they compare? IDEXX Laboratories, Inc. trades at $554.7 (market cap $44.48B), while TORM plc trades at $29.89 (market cap $2.99B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.9× TORM plc's market cap, and TORM plc pays a 9.62% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TRMD | |
|---|---|---|
Market Cap | $44.48B | $2.99B |
Sector | Health | Technology |
52-Week High | $766.68 | $34.87 |
52-Week Low | $520.87 | $17.50 |
Enterprise Value | $45.38B | $3.88B |
Dividend Yield | — | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
TRMD trades at $29.08, up 2.21% today, with a neutral technical signal. The company reported strong profitability with a 24.41% net income margin and a low P/E of 8.34. Recent earnings showed a Q1 2026 miss but Q4 2025 beat, with Q2 2026 results pending. Cash flow from operations remains robust at $552 million in 2026, though net cash flow is negative. A $0.70 dividend for H1 2026 is scheduled, reflecting shareholder returns.
Outlook is positive due to strong fundamentals and 100% buy ratings from analysts, but risks include earnings volatility and negative net cash flow. The stock offers value with attractive valuation metrics and dividend yield, though investors should monitor Q2 earnings and cash flow trends for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
